Watch recordings from our past Educational Events at your leisure anywhere and anytime! Our E-Education has more than 400 presentations that cover important Alpha-1 related topics.
You can also search for more presentations on Vimeo at http://vimeo.com/a1f
This program provides the Alpha-1 Community with access to educational programs from our National Conference and National Education Series.
We gratefully acknowledge all our speakers who volunteered their time and gave permission to record and disseminate their presentations.
Click For Search Options
Sara Wienke attended the University of North Carolina at Chapel Hill and obtained a Bachelor of Science degree in Biology with a minor in chemistry. She obtained her Master of Science degree in Genetic Counseling at the University of North Carolina at Chapel Hill. After graduate school, Ms. Wienke moved to Charleston, SC where she has been working at the Medical University of South Carolina (MUSC) as the Program Director of the Alpha-1 Association Genetic Counseling Program for the past year. She had previously taught undergraduate biology labs at UNCG and worked as a lab manager in Cell Biology at Duke University.
Michael Campos, M.D. is the Assistant Professor of Clinical Medicine at the Division of Pulmonary and Critical Care Medicine at the University of Miami. He graduated from Cayetano Heredia University in Lima, Peru and did all his postgraduate training at the University of Miami. He is board certified in Internal Medicine, Pulmonary Diseases and Critical Care Medicine. He joined the University of Miami after graduation in 2003 and has been an active researcher in COPD and alpha-1 antitrypsin deficiency, performing both clinical and basic science studies. His principal areas of interest include the pathophysiology of airway disease in Alpha-1, the prevalence of Alpha-1 in Hispanics and outcome studies in Alpha-1. His work has led to several recent publications about Alpha-1 in peer reviewed journals.
Mr. Walsh is the co-founder, President and CEO of the Alpha-1 Foundation in Miami, Florida. Under his leadership, the organization has become internationally recognized and has invested more than $28 million to support Alpha-1 research and research-related projects, which includes funding grant awards to more than 50 academic institutions in North America and Europe. Mr. Walsh is also co-founder and President of AlphaNet, Inc. a not-for-profit disease management services company providing comprehensive care exclusively for individuals with Alpha-1 Antitrypsin Deficiency. AlphaNet, Inc. currently provides services to 2,500 individuals with Alpha-1 in all 50 states, Puerto Rico and the Virgin Islands. Due to the infrastructure and support provided by the Foundation and AlphaNet, several companies have drugs in development for the treatment of Alpha-1. In 2002 Mr. Walsh’s contribution to pioneering collaboration in orphan drug development was recognized by the FDA with the Commissioner’s Special Citation. Mr. Walsh has an extensive background in business management and government relations; he served three terms on the Advisory Committee on Blood Safety and Availability (1997-2006), is Immediate-Past Chairperson of the National Health Council’s Board of Directors (2005-2006), he is Past Chair and a member of the American Thoracic Society Public Advisory Roundtable (PAR) and was the Presidential Appointee (2004-2005) of the American Thoracic Society’s Board of Directors. He is a member of the American Lung Association National Action Panel on Lung Disease, is on the Advisory Board of the Center for Genetic Research Ethics And Law (CGREAL) at Case Western Reserve University, is a Trustee on the Foundation of the American Thoracic Society (2006-2008) is a member of the US COPD Coalition Executive Committee, Chair of the International COPD Coalition (2006-2008), and a member of the COPD Foundation Board of Directors. He regularly testifies before Congress and advisory groups as a patient advocate. Mr. Walsh was diagnosed with the rare genetic disorder, Alpha-1 Antitrypsin Deficiency, in 1989.
Robert “Sandy” Sandhaus graduated from Haverford College in Pennsylvania with a degree in molecular biology. He then received a PhD in cell biology and an MD from the State University of New York at Stony Brook. He completed his residency in internal medicine at the Beth Israel Hospital in Boston and a pulmonary fellowship at the University of California San Francisco (UCSF). He was then appointed to the UCSF medical faculty and subsequently joined the medical faulty at the University of Colorado School of Medicine in 1981 where he founded the Alpha1-Antitrypsin Deficiency Program at National Jewish Medical and Research Center in Denver and remains its director. His research throughout his academic career has centered on the role of white blood cell enzymes in the prevention and promotion of lung disease. This work led to a special clinical interest in patients with the genetic deficiency of alpha-1 antitrypsin. In addition to his ongoing academic career. Dr. Sandhaus briefly left medical practice to work in research and development in the biopharmaceutical industry. He ran clinical development programs at Cortech, NeXstar Pharmaceuticals, and Gilead Sciences. Dr. Sandhaus has served on the Boards of Directors of the Alpha-1 Association, the Alpha-1 Foundation, AlphaNet, and the Osteogenesis Imperfecta Foundation. For the past five years, he has been the Executive Vice President and Medical Director of AlphaNet and the Clinical Director of the Alpha-1 Foundation. He is board certified in internal medicine, pulmonary disease, and critical care medicine. He lives in Bow Mar, Colorado.
For the past 15 years Dr. Stocks has been a faculty member of the University of Texas Health Center at Tyler. His major research focus has been Alpha-1 Antitrypsin Deficiency. He was a principal investigator in the NHLBI registry of patients with severe Alpha-1 Deficiency from 1988-1995. Over the last decade Dr. Stocks has participated as a principal investigator in almost every pharmaceutical trial for Alpha-1 conducted in the United States. He is a member of the Alpha-1 Foundation's Medical and Scientific Advisory Committee with responsibilities for oversight of the Research Registry. He is a past member of the Alpha-1 Association's Board of Directors.
Martin R. Zamora, M.D., is Professor of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, at the University of Colorado at Denver School of Medicine, Aurora, Colorado. He is the Medical Director of Lung Transplantation, at the University of Colorado at Denver Health Sciences Center. He received his medical degree from the University of Colorado School of Medicine, and did his internship and residency in Internal Medicine and Pulmonary and Critical Care Fellowship at The University of Colorado Health Sciences Center, Denver. Dr. Zamora has been a member of the American Society of Transplantation Thoracic Committee, a member of the United Network for Organ Sharing Board of Directors, the UNOS Thoracic Committee and Chaired the Lung Allocation Subcommittee and was involved in the development and implementation of the Lung Allocation System. He is a member of several other professional societies. He is the author of several book chapters and over 150 articles and abstracts published in peer-reviewed journals. Dr. Zamora has been an NIH funded researcher, has been the principal investigator of multiple industry sponsored studies, and has been awarded many honors, including most recently the America's Top Doctors Award in 2009 and the Best Doctors in America Award for 2009-2010. His research interests include mechanisms of transplant rejection and the role of viral infections in lung transplant outcomes and the prevention and management of cytomegalovirus infection following solid organ transplantation.
Kyle Hogarth received his medical degree from Case Western Reserve University in Cleveland and completed his residency in internal medicine and a fellowship in pulmonary and critical care medicine at the University of Chicago Medical Center. Dr. Hogarth’s research focuses on improving quality of life and outcomes for patients with AAT deficiency, improving AAT deficiency diagnosis, and improving the early detection and management of lung cancer. He is an investigator in numerous clinical trials for these diseases. In 2009, he received the Department of Medicine Residency Award for Outstanding Teaching. In 2011 and 2007, he received the Department of Medicine’s Outstanding Faculty Clinical Service Award. In addition to his clinical and research work, he is on the Editorial Board for the journals of CHEST and Proceedings of the American Thoracic Society. He runs a large clinic devoted to the care of Alpha-1 patients.
Minneapolis Alpha-1 Education Day
Alphas of Northern Illinois Support Group
Alphas of Northern Illinois Support Group Meeting - Rockford, IL
West Texas Alphas Support Group
West Texas Alphas Support Group Meeting - Lubbock, TX
Reno/Tahoe Alpha-1 Support Group
Reno/Tahoe Alpha-1 Support Group Meeting - Reno, NV
Dakotaland Alphas Support Group
Dakotaland Alphas Support Group Meeting - Sioux Falls, SD
SoCal Roadrunners Alpha-1 Support Group
SoCal Roadrunners Alpha-1 Support Group Meeting - Palm Desert, CA
Glass City & MI Alphas: Walk on the Wild Side
Northwest Indiana (NWI) Alpha-1 Support Group
Northwest Indiana (NWI) Alpha-1 Support Group Meeting – Dyer, IN
Thank you to our generous program sponsors.
3300 Ponce de Leon Blvd. Coral Gables, FL 33134
Phone: (877) 228-7321 Email: email@example.com